Extremely low levels of epidermal skin-derived antileucoproteinase/elafin in a patient with impetigo herpetiformis

British Journal of Dermatology

Volumn 137, Issue 1, 1997, Pages 123-129

  Kuijpers, A L A ^a   Schalkwijk, J ^a   Rulo, H F C ^a   Peperkamp, J J A ^b   Van De Kerkhof, P C M ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SLINGELAND HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ELAFIN;

ADULT; ARTICLE; BLOOD LEVEL; CASE REPORT; DISEASE COURSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMPETIGO HERPETIFORMIS; PREGNANCY; PRIORITY JOURNAL; PUSTULAR PSORIASIS; TISSUE LEVEL;

EID: 0030794362     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb03714.x     Document Type: Article

References (30)

1. Takematsu H, Terui T, Ohkohchi K et al. Presence of chemotactic peptides other than C5a anaphylatoxin in scales of psoriasis and sterile pustular dermatoses. Acta Derm Venereol (Stockh) 1986: 66: 93-7.
2. Ternowitz T. Monocyte and neutrophil chemotaxis in psoriasis. Relation to the clinical status and the type of psoriasis. J Am Acad Dermatol 1986; 15: 1191-9.
3. Lundin A, Hakansson L, Michaelsson G, Venge P. Neutrophil locomotion and serum chemotactic and chemokinetic activities in pustulosis palmoplantaris compared with psoriasis. Arch Dermatol Res 1987; 279: 385-91.
4. Chang A, Schalkwijk J, Happle R, van de Kerkhof PCM. Elastase-inhibiting activity in scaling skin disorders. Acta Derm Venereol (Stockh) 1990; 70: 147-51.
5. Schalkwijk J, de Roo C, de Jongh GJ. Skin-derived antileukoproteinase (SKALP) an elastase inhibitor from human keratinocytes. Purification and biochemical properties. Biochim Biophys Acta 1991; 1096: 148-54.
6. Schalkwijk J, Chang A, Janssen P et al. Skin-derived antileucoproteinases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br J Dermatol 1990; 122: 631-41.
7. Wiedow O, Schroder JM, Gregory H et al. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem 1990; 265: 14791-5.
8. Sallenave JM, Marsden MD, Ryle AP. Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions. Evidence of sequence homology and immunological cross-reactivity. Biol Chem Hoppe Seyler 1992; 373: 27-33.
9. Wiedow O, Lüdemann J, Utecht B. Elafin is a potent inhibitor of proteinase 3. Biochem Biophys Res Commun 1991; 174: 6-10.
10. Pfundt R, van Ruissen F, van Vlijmen-Willems IMJJ et al. Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia. J Clin Invest 1996; 98: 1389-99.
11. Kuijpers ALA, Zeeuwen PLJM, de Jongh GJ et al. Skin-derived antileukoproteinase (SKALP) is decreased in pustular forms of psoriasis. A clue to the pathogenesis of pustule formation? Arch Dermatol Res 1996: 288: 641-7.
12. Alkemade HAC, van de Kerkhof PCH, Schalkwijk J. Demonstration of skin-derived antileukoproteinase (SKALP) in urine of psoriatic patients. J Invest Dermatol 1992: 99: 3-7.
13. Fritz H. Human mucus proteinase inhibitor (human MPI). Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI). Biol Chem Hoppe Seyler 1988: 369 (Suppl.): 79-82.
14. Nadziejko C, Finkelstein I, Balmes JR. Contribution of secretory leukocyte proteinase inhibitor to the antiprotease defense system of the peripheral lung: effect of ozone-induced acute inflammation. Am J Respir Crit Care Med 1995: 152: 1592-8.
15. Stockley RA, Morrison HM. Elastase inhibitors of the respiratory tract. Eur Respir J 1990; 9 (Suppl.): 9s-15s.
16. Oosterling RJ, Nobrega RE, Du Boeuff JA, Van Der Meer JB, Impetigo herpetiformis or generalized pustular psoriasis? Arch Dermatol 1978: 114: 1527-9.
17. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968; 80: 771-93.
18. Lotem M, Katzenelson V, Rotem A et al. Impetigo herpetiformis: a variant of pustular psoriasis or a separate entity? J Am Acad Dermatol 1989; 20: 338-41.
19. Beveridge GW, Harkness RA, Livingstone JR. Impetigo herpetiformis in two successive pregnancies. Br J Dermatol 1966; 78: 106-12.
20. Oumeish OY, Farraj SE, Bataineh AS. Some aspects of impetigo herpetiformis. Arch Dermatol 1982: 118: 103-5.
21. Ott F, Krakowski A, Tur E et al. Impetigo herpetiformis with lowered serum level of vitamin D and its diminished intestinal absorption. Dermatologica 1982; 164: 360-5.
22. Bajaj AK, Swarup V, Gupta OP, Gupta SC. Impetigo herpetiformis. Dermatologica 1977; 155: 292-5.
23. Risum G. Psoriasis exacerbated by hypoparathyroidism with hypocalcaemia. Br J Dermatol 1973: 89: 309-12.
24. Vickers HR, Sneddon IB. Psoriasis and hypoparathyroidism. Br J Dermatol 1963; 75: 419-21.
25. Holm AL, Goldsmith LA. Impetigo herpetiformis associated with hypocalcemia of congenital rickets. Arch Dermatol 1991; 127: 91-5.
26. Thio HB, Vermeer BJ. Hypocalcemia in impetigo herpetiformis: a secondary transient phenomenon? Arch Dermatol 1991; 127: 1587-8.
27. Winzer M, Wolff HH. Impetigo herpetiformis. Hautarzt 1988; 39: 110-3.
28. Chang A, Schalkwijk J, Happle R, van de Kerkhof PCM. Elastase-inhibiting activity in scaling skin disorders. Acta Derm Venereol (Stockh) 1990; 70: 147-51.
29. Alkemade HAC, Molhuizen HOF, van Vlijmen Willems IMJJ, et al. Differential expression of SKALP/elafin in human epidermal tumors. Am J Pathol 1993; 143: 1679-87.
30. Alkemade HAC, de Jongh GJ, Arnold WP et al. Levels of skin-derived antileukoproteinase (SKALP)/elafin in serum correlate with disease activity during treatment of severe psoriasis with cyclosporin A. J Invest Dermatol 1995; 104: 189-93.